Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-08-25
2010-06-15
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S343000, C514S423000
Reexamination Certificate
active
07737137
ABSTRACT:
Methods for treating a mammal suffering from glucocorticoid-related diseases and conditions, comprising administering to the mammal an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the inhibitor is a compound of formula (I):or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
REFERENCES:
patent: 4324791 (1982-04-01), Welstead, Jr.
patent: 6368816 (2002-04-01), Walker et al.
patent: 6784167 (2004-08-01), Wood et al.
patent: 7087400 (2006-08-01), Walker et al.
patent: 7122531 (2006-10-01), Walker et al.
patent: 1180513 (2002-02-01), None
patent: 03059905 (2003-07-01), None
patent: 2004011310 (2004-02-01), None
patent: 2004089470 (2004-10-01), None
patent: 2005108361 (2005-11-01), None
patent: 2006104280 (2006-10-01), None
Anstead, Adv. Wound Care, 11:277-285 (1998).
Armaly, Arch. Ophthalmol. 78:193-197 (1967).
Baxter, Pharmac. Ther., 2:605-659 (1976).
Beer, et al., Vitamins & Hormones, 59:217-239 (2000).
Belanoff, et al., J. of Psych. Res., 35:127-145 (2001).
Bertagna, et al., Cushing's Dis. In: Melmed S., Ed. The Pituitary, 2ndEd. (Chapt. 13): 592-612 (2002).
Billaudel, et al., Horm. Metab. Res., 11:555-560 (1979).
Bland, et al., J. of Endocrin. 61:455-464 (1999).
Boscaro, et al., The Lancet, 357:783-791 (2001).
Budziszewska, Polish Journal of Pharm., 54: 343-349 (2002).
Cooper, et al., Bone, 27(3): 375-381 (2000).
Cooper, et al., J. of Bone & Mineral Res., 17(6): 979-986 (2002).
Davani, J. of Biol. Chem., 275 (45): 334841-34844 (2000).
DeBattista, et al., Trends in Endoc. Metab., 17:117-120 (2006).
de Quervain, et al., Hum. Molec. Genetics, 13(1): 47-52 (2004).
Gomez-Sanchez, et al, Am. Journal of Physiol., 263 (6 pt 1): E2236-E1130 (1992).
Greene, et al., Protecting Groups in Chemical Synthesis (3rded.), John Wiley & Sons, NY, Table of Contents (1999).
Hammami, et al., J. of Clin. Endocrin. & Metab., 73(2): 326-334 (1991).
Hermanowski-Vosatka, et al., J. of Exp. Med., 202(4): 517-527 (2005).
Higuchi, et al., Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (Table of Contents).
Hodge, et al., Exp. Physiol., 87:1-8 (2002).
Issa, et al., J. of Neurosci. 10(10): 3247-3254 (1990).
Jones, et al., J. Org. Chem. 63: 2758-2760, (1998).
Kerr et al., Psychobiology, 22: 123-133 (1994).
Kolocouris, et al., J. Med. Chem., 39:3307-3318 (1996).
Kornel, et al., Steroids, 58:580-587 (1993).
Landfield, Science, 272: 1249-1251 (1996).
Lupien, et al., Nature Neurosci. 1(1): 69-73 (1998).
Mason, Immun. Today, 12(2): 57-60 (1991).
Masuzaki, et al., Science, 294:2166-2170 (2001).
Masuzaki, et al., J. of Clin. Invest. 112(1): 83-90 (2003).
McEwen, Metab. Clin. And Exp., 54: 20-23 (2005).
Monder, et al., Vitamins and Hormones, 47: 187-271 (1983).
Montague, Diabetes, 49(6): 883-888 (2000).
Morton, et al., J. of Biol. Chem., 276(44): 41293-41500 (2001).
Norman et al., Expert Rev. Neurotherapeutics 7: 203-213 (2007).
Orth, Med. Prog. 332(12): 791-803 (1995).
Ortsäter, et al., Diabetes Metab. Res. Rev., 21:359-366 (2005).
Paterson, et al., Proc. Natl. Acad. Sci., 101(18): 7088-7093 (2004).
Pirpiris, et al., Hypertention, 19:567-574 (1992).
Rauz, et al., Invest. Ophthal. & Vis. Sci., 42(9): 2037-2042 (2001).
Rauz, et al., Q. J. Med., 96:481-490 (2003).
Rehman, et al., Med. Pediatr. Oncol 41:212-216 (2003).
Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
Rook, Baillier's Clin. Endocrinol. Metab. 13:576-581 (1999).
Schteingart, Princ. & Prac. of Endoc. & Metab. Chapt. 75:723-728 (2001).
Seckl, et al., Endocrinology, 142: 1371-1376, 2001.
Small, et al., Proc. Natl. Acad. Sci., 102(34): 12165-12170 (2005).
Stokes, et al., Invest. Ophthalmol. Vis. Sci., 44:5163-5167 (2003).
Strohle, et al., Pharmacopsychiatry, 36: S207-S214 (2003).
Thekkapat, et al., Proc. Natl. Acad. Sci. USA, 101: 6743-6749 (2004).
Tronche, et al., Nature Genetics, 23:99-103 (1999).
Turner, et al., Calcif. Tissue Int., 56:311-315 (1995).
Walker, et al., Clin. Sci., 82:597-605 (1992).
Walker, et al., J. of Clin. Endocrin. & Metab. 80(11): 3155-3159 (1995).
Walker, et al, PNAS, 102: 12165-70 (2005).
Wolkowitz, et al., Ann. NY Acad. Sci., 1032:191-194 (2004).
Woolley, Brain Res., 531: 225-231 (1990).
Yau, et al., Neuroscience, 66: 571-581 (1995).
Yau, et al., Proc. Natl. Acad. Sci. USA. 98: 4716-4712 (2001).
Yeh, et al., Org. Letters, 8(18): 3963-3966 (2006).
Brune Michael E.
Fung Steven
Jacobson Peer B.
Kurukulasuriya Ravi
Link James T.
Abbott Laboratories
Desai Rita J
Mabry John
Sreenivasarao Vepachedu
LandOfFree
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248470